title: Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
abstract: The aim of this study was to analyze serum changes in mediators of fibrogenesis and in non-invasive markers of liver fibrosis among HIV/HCV-coinfected patients starting maraviroc (MVC)-based antiretroviral therapy. Patients included in this prospective pilot study met the following criteria: (1) HIV-infection, (2) detectable serum HCV-RNA, and ((3) started MVC. Transforming growth factor-β1 (TGF-beta1), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were measured in serum samples at baseline and 6 months after starting MVC. AST-to-platelet ratio index (APRI) was assessed at the same time points. Twenty-four patients were analyzed. Median (IQR) serum levels at baseline and after 6 months on MVC of TGF-beta1 were 27,295 (20,562-36,844) and 33,753 (18,973-46,130) pg/mL (p=0.116), of MMP-2 were 216 (186-274) and 241 (194-306) ng/mL (p=0.247), and of TIMP-1 were 237 (170-284) and 216 (171-271) ng/mL (p=0.415). APRI levels were 0.99 (0.53-3.46) at baseline and 0.83 (0.48-2.34) at 6 months (p=0.16). Serum mediators of liver fibrogenesis and fibrosis do not change significantly in HIV/HCV-coinfected patients in the short-term after starting MVC. As TGF-beta1 levels have been shown to increase over time in HCV infection and liver fibrosis worsens rapidly in HIV/HCV coinfection, these parameters seem to evolve in a different way in MVC-treated patients.
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avda. Bellavista s/n., 41014, Seville, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Macías
authors.forename: M M
authors.initials: MM
authors.lastname: Viloria
authors.forename: A
authors.initials: A
authors.lastname: Rivero
authors.forename: I
authors.initials: I
authors.lastname: de los Santos
authors.forename: M
authors.initials: M
authors.lastname: Márquez
authors.forename: J
authors.initials: J
authors.lastname: Portilla
authors.forename: F
authors.initials: F
authors.lastname: Di Lello
authors.forename: A
authors.initials: A
authors.lastname: Camacho
authors.forename: J
authors.initials: J
authors.lastname: Sanz-Sanz
authors.forename: G
authors.initials: G
authors.lastname: Ojeda
authors.forename: R
authors.initials: R
authors.lastname: Mata
authors.forename: J
authors.initials: J
authors.lastname: Gómez-Mateos
authors.forename: J A
authors.initials: JA
authors.lastname: Pineda
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D015415:Biomarkers / Q000097:blood*; D003510:Cyclohexanes / Q000008:administration & dosage; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008297:Male; D000077592:Maraviroc; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood / Q000302:isolation & purification; D044967:Serum / Q000737:chemistry*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D016212:Transforming Growth Factor beta / Q000097:blood; D014230:Triazoles / Q000008:administration & dosage
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D003510:Cyclohexanes; D012367:RNA, Viral; C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D016212:Transforming Growth Factor beta; D014230:Triazoles; D020778:Matrix Metalloproteinase 2; D000077592:Maraviroc